MAP3K7 and neoplasm: Additional studies are required to understand this result, which could be due to low penetrations of HS-276 through the blood-brain barrier, effects of TAK1 inhibition on cells in the TME restricting tumor growth or the stability and potency of the compound in inhibiting TAK1 in this tumor context.